Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients

Tiago Torres, Margarida Gonçalo, Maria João Paiva Lopes, Cristina Claro, Leonor Ramos, Manuela Selores, Pedro Mendes Bastos, Joana Rocha, Rodrigo Carvalho, Alberto Mota, Paulo Filipe on Behalf of the Atopic Dermatitis Group of the Portuguese Society of Dermatology and Venereology

Abstract

Atopic dermatitis is a highly prevalent chronic, immune-mediated inflammatory skin disease with a significant burden on patients, families and healthcare systems. This article presents recommendations developed by the Atopic Dermatitis Group of the Portuguese Society of Dermatology and Venereology addressing several clinical questions that arise in the management and care of moderate-to-severe atopic dermatitis with biologic agents and Janus kinase (JAK) inhibitors based on the available evidence. The recommendations were generated after a thorough evaluation of existing guidelines on the treatment of atopic dermatitis, publications concerning new biologics and JAK inhibitors not yet incorporated into existing guidelines, and expert-based recommendations. It also includes considerations on atopic dermatitis severity, indications for initiating biologic agents and JAK inhibitors, parameters to be considered in the treatment choice, in particular treatment goals, and recommendations for the use, screening and monitoring of these therapies.

Article Details

Article Type

Recommendation

DOI

10.7573/dic.2021-9-5

Categories

Publication Dates

Accepted: ; Published: .

Citation

Torres T, Gonçalo M, Paiva Lopes MJ, Claro C, Ramos L, Selores M, Mendes Bastos P, Rocha J, Carvalho R, Mota A, Filipe P on Behalf of the Atopic Dermatitis Group of the Portuguese Society of Dermatology and Venereology. Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients. Drugs Context. 2021;10:2021-9-5. https://doi.org/10.7573/dic.2021-9-5

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.